Emcure Pharmaceuticals Limited IPO Opens On July 03. Check IPO Details Issue Date Price

EspressoLogy

Emcure Pharmaceuticals Limited IPO Opens On July 03. Check IPO Details Issue Date Price

July 03, 2024
Emcure Pharmaceuticals Limited IPO Opens On July 03. Check IPO Details Issue Date Price

Emcure Pharmaceuticals Limited is coming out with an initial public offer to raise Rs. 1952 crores from the market.

Below are the details of the Emcure Pharmaceuticals Limited IPO:

  • Issue opens – July 03 (Wednesday)
  • Issue closes – July 05 (Friday)
  • Issue size – Rs. 1952 crores
  • Price band – Rs. 960 to 1,008 per equity share
  • Bid lot – 14 shares and in multiples thereof.

And here are some details of the company and further details on the IPO.

Company Details:

  • Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. They are a research and development (“R&D”) driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled them to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. They were ranked as (i) the 13th largest pharmaceutical company in India in terms of Domestic Sales for MAT Financial Year 2024, (ii) the 4th largest pharmaceutical company by market share in their Covered Markets in terms of Domestic Sales for MAT Financial Year 2024, and (iii) the largest pharmaceutical company in the gynecology and human immunodeficiency virus (“HIV”) antivirals therapeutic areas in India in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
  • Their competitive advantage in the domestic market stems from their differentiated product portfolio, which has allowed them to establish their presence in most of the major therapeutic areas, including gynecology, cardiovascular, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/anti-neoplastics. Across the gynecology, vitamins, minerals and nutrients, HIV antivirals, blood-related and oncology/antineoplastics therapeutic areas, they were ranked among the 10 largest pharmaceutical companies in India in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).
  • They have demonstrated strong capabilities and a proven track record in building brands. Six of their brands were ranked among the 300 highest selling brands in the IPM, in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report). They had 26 brands with Domestic Sales of over ?500.00 million for MAT Financial Year 2024, as compared to 13 brands for MAT Financial Year 2020 (Source: CRISIL Report). In addition, 16 of their top 20 brands were each ranked among the three highest selling brands in their respective therapeutic areas in the IPM, in terms of Domestic Sales for MAT Financial Year 2024 (Source: CRISIL Report).

Issue Size : Rs.1952 Cr

Employee Reservation : Up to 1,08,900 equity shares

Employee Discount : Rs.90 per share

Issue break-up :

QIB – 50 % of the net offer – Rs. 971.01 Cr.
NIB – 15 % of the net offer – Rs. 291.30 Cr.
RET – 35 % of the net offer – Rs. 679.71 Cr.

Listing : BSE & NSE

Registrar : Link Intime India Private Limited

UPI : All Retail & NII Bidders (bids up to Rs. 5,00,000) Applications through brokers are compulsorily in UPI Mode

Note:

Application made using third party UPI or ASBA Bank A/c are liable to be rejected.

The UPI Mandate acceptance time for Retail and NII Bidders (bids up to Rs. 5,00,000) shall expire at 5:00 PM on the closing day of the IPO i.e., Friday, 5th July 2024.

Not an Espresso customer, but still want to apply for the IPO? Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.